Although further studies are necessary to dissect the molecular events that link collagen GGT activity to cancer progression, our data raise the tantalizing possibility that drugs that target LH2’s GLT active site could be useful for the treatment of LUAD and other LH2-dependent cancer types. This evidence concerns the gene PLOD2 and cancer.